Phathom Pharmaceuticals, Inc. (PHAT) Tops Q4 EPS by 42c

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q4 EPS of ($0.79), $0.42 better than the analyst estimate of ($1.21). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $26.04 million.

For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.

You May Also Be Interested In

• BofA says convenience store sales trail broader retail channels
• iShares iBoxx $ High Yield Corporate Bond ETF (HYG) call put ratio 5.7 calls to 1 put with a focus on 50K contracts of September 50 calls
• Prenetics Global (PRE) Tops Q2 EPS by 18c